Status:

UNKNOWN

Effect of Oral N-Acetyl Cysteine in Prevention of Necrotizing Enterocolitis in Preterm Neonates With Feeding Intolerance

Lead Sponsor:

Ain Shams University

Conditions:

Preterm Neonates and Feeding Intolerance

Necrotizing Enterocolitis

Eligibility:

All Genders

Phase:

PHASE4

Brief Summary

necrotizing enterocolitis is a dangerous disease that may be fatal especially in preterm neonates, the early features of the disease are symptoms of feeding intolerance and interruption of the baby's ...

Eligibility Criteria

Inclusion

  • preterm neonates (less than or = 36 weeks gestational age )
  • feeding intolerance

Exclusion

  • active gastro-intestinal tract bleeding
  • Gastro- intestinal tract surgical problem
  • Congenital gastro-intestinal tract anomalies
  • evidence of allergy to NAC
  • use of prebiotics or probiotics

Key Trial Info

Start Date :

January 1 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

March 30 2024

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT06202911

Start Date

January 1 2023

End Date

March 30 2024

Last Update

January 12 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Ain Shams university hospitals

Cairo, Egypt, 1234

Effect of Oral N-Acetyl Cysteine in Prevention of Necrotizing Enterocolitis in Preterm Neonates With Feeding Intolerance | DecenTrialz